The rejection is not due to the therapy’s formulation, safety or efficacy, according to the drugmaker. Instead, the FDA’s response “is related to observations as part of a standard pre-approval inspection at a manufacturing facility,” J&J said in a Dec. 16 statement.
Rybrevant (amivantamab) is currently approved in an intravenous presentation. The experimental injection drug combines amivantamab and recombinant human hyaluronidase.
J&J said it is working with the FDA to bring the formulation to market.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
